Volpara Solutions Limited
RELATED CONTENT
October 15, 2020 — Fujifilm Medical Systems U.S.A., Inc., a leading provider of diagnostic imaging and medical ...
October 15, 2020 
June 9, 2020 — More than 75 percent of hospitals and imaging centers that perform mammography across the United States ...
June 09, 2020 
April 7 2020 — Volpara Solutions announced it is collaborating with DetectED-X, an online radiology training and ...
April 07, 2020 
Celebrating its 10th Anniversary in 2019, Volpara Solutions remains committed to helping breast imaging centers achieve ...
October 01, 2019 
Volpara Solutions and ScreenPoint Medical BV signed an agreement under which Volpara will sell ScreenPoint's Transpara products to breast imaging clinics in the United States, Australia, New Zealand and parts of Asia. Transpara is designed to assist radiologists with the reading of mammograms and is one of the first next-generation artificial intelligence (AI) applications for detecting breast cancer in screening mammograms to gain 510(k) clearance from the U.S. Food & Drug Administration (FDA).
August 02, 2019 
Volpara Health Technologies, Volpara Solutions' parent company, has signed a binding agreement to acquire U.S.-based MRS Systems Inc. (MRS).
June 04, 2019 
Research has demonstrated use of Volpara Solutions' VolparaDensity software in combination with the Tyrer-Cuzick Breast Cancer Risk Evaluation Tool improves breast cancer risk stratification. The research suggests VolparaDensity could be used to help guide personalized medicine through risk-adapted screening.
May 22, 2019 
Volpara Solutions announced the launch of an expanded agreement enabling the worldwide distribution of its VolparaDensity software by GE Healthcare.
March 26, 2019 
Volpara Solutions Inc. received U.S. Food and Drug Administration (FDA) 510(k) clearance for new technologies used in the Volpara Density clinical application for breast density assessment. The updated version of VolparaDensity more accurately reflects breast density from images captured using the Hologic SmartCurve system.
January 31, 2019 
ScreenPoint Medical has signed a memorandum of understanding (MOU) with Volpara Health Technologies. Volpara will deliver ScreenPoint’s artificial intelligence (AI)-based products to customers as part of its expanding VolparaEnterprise AI cloud ecosystem. Together, the two companies expect to improve the clinical performance of mammography and drive the earlier detection of breast cancer. The partnership will leverage Volpara’s growing footprint in the breast imaging marketplace and will provide an opportunity for ScreenPoint to enter the U.S. market.
December 04, 2018